Literature DB >> 31465300

TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding.

Tine Wyseure1, Tingyi Yang1, Jenny Y Zhou2, Esther J Cooke1,2, Bettina Wanko3,4,5, Merissa Olmer1, Ruchi Agashe1, Yosuke Morodomi1, Niels Behrendt6, Martin Lotz1, John Morser3, Annette von Drygalski1,2, Laurent O Mosnier1.   

Abstract

Excessive vascular remodeling is characteristic of hemophilic arthropathy (HA) and may contribute to joint bleeding and the progression of HA. Mechanisms for pathological vascular remodeling after hemophilic joint bleeding are unknown. In hemophilia, activation of thrombin-activatable fibrinolysis inhibitor (TAFI) is impaired, which contributes to joint bleeding and may also underlie the aberrant vascular remodeling. Here, hemophilia A (factor VIII-deficient; FVIII-deficient) mice or TAFI-deficient mice with transient (antibody-induced) hemophilia A were used to determine the role of FVIII and TAFI in vascular remodeling after joint bleeding. Excessive vascular remodeling and vessel enlargement persisted in FVIII-deficient and TAFI-deficient mice, but not in transient hemophilia WT mice, after similar joint bleeding. TAFI-overexpression in FVIII-deficient mice prevented abnormal vessel enlargement and vascular leakage. Age-related vascular changes were observed with FVIII or TAFI deficiency and correlated positively with bleeding severity after injury, supporting increased vascularity as a major contributor to joint bleeding. Antibody-mediated inhibition of uPA also prevented abnormal vascular remodeling, suggesting that TAFI's protective effects include inhibition of uPA-mediated plasminogen activation. In conclusion, the functional TAFI deficiency in hemophilia drives maladaptive vascular remodeling in the joints after bleeding. These mechanistic insights allow targeted development of potentially new strategies to normalize vascularity and control rebleeding in HA.

Entities:  

Keywords:  Angiogenesis; Coagulation; Hematology; Rheumatology

Year:  2019        PMID: 31465300      PMCID: PMC6795396          DOI: 10.1172/jci.insight.128379

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  75 in total

1.  Ultrasound detects joint damage and bleeding in haemophilic arthropathy: a proposal of a score.

Authors:  D Melchiorre; S Linari; M Innocenti; I Biscoglio; M Toigo; M M Cerinic; M Morfini
Journal:  Haemophilia       Date:  2010-11-11       Impact factor: 4.287

2.  Guidelines for the management of hemophilia.

Authors:  A Srivastava; A K Brewer; E P Mauser-Bunschoten; N S Key; S Kitchen; A Llinas; C A Ludlam; J N Mahlangu; K Mulder; M C Poon; A Street
Journal:  Haemophilia       Date:  2012-07-06       Impact factor: 4.287

3.  Successful treatment of severe bleeding in hemophilic target joints by selective angiographic embolization.

Authors:  Eveline P Mauser-Bunschoten; Jacco A C Zijl; Willem Mali; A Cees van Rinsum; H Marijke van den Berg; Goris Roosendaal
Journal:  Blood       Date:  2004-12-21       Impact factor: 22.113

4.  Urokinase-mediated fibrinolysis in the synovial fluid of rheumatoid arthritis patients may be affected by the inactivation of single chain urokinase type plasminogen activator by thrombin.

Authors:  E A Braat; A F Jie; H K Ronday; B Beekman; D C Rijken
Journal:  Ann Rheum Dis       Date:  2000-04       Impact factor: 19.103

5.  Endovascular Management of Recurrent Spontaneous Hemarthrosis After Arthroplasty.

Authors:  Marcin K Kolber; Pratik A Shukla; Abhishek Kumar; Adam Zybulewski; Todd Markowitz; James E Silberzweig
Journal:  Cardiovasc Intervent Radiol       Date:  2016-11-23       Impact factor: 2.740

6.  Availability of angiography and therapeutic embolization for the treatment of acute bleeding in patients with hemophilia.

Authors:  Mi Jin Kim; Ji Young Oh; Young Shil Park
Journal:  Int J Hematol       Date:  2017-08-16       Impact factor: 2.490

7.  Neoangiogenesis contributes to the development of hemophilic synovitis.

Authors:  Suchitra S Acharya; Rosandra N Kaplan; Dan Macdonald; Oluwa T Fabiyi; Donna DiMichele; David Lyden
Journal:  Blood       Date:  2010-12-16       Impact factor: 22.113

8.  The thrombomodulin-protein C system is essential for the maintenance of pregnancy.

Authors:  Berend Isermann; Rashmi Sood; Rafal Pawlinski; Mark Zogg; Shawn Kalloway; Jay L Degen; Nigel Mackman; Hartmut Weiler
Journal:  Nat Med       Date:  2003-02-10       Impact factor: 53.440

Review 9.  Advances and challenges in hemophilic arthropathy.

Authors:  Tine Wyseure; Laurent O Mosnier; Annette von Drygalski
Journal:  Semin Hematol       Date:  2015-10-26       Impact factor: 3.851

10.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

Authors:  Marilyn J Manco-Johnson; Thomas C Abshire; Amy D Shapiro; Brenda Riske; Michele R Hacker; Ray Kilcoyne; J David Ingram; Michael L Manco-Johnson; Sharon Funk; Linda Jacobson; Leonard A Valentino; W Keith Hoots; George R Buchanan; Donna DiMichele; Michael Recht; Deborah Brown; Cindy Leissinger; Shirley Bleak; Alan Cohen; Prasad Mathew; Alison Matsunaga; Desiree Medeiros; Diane Nugent; Gregory A Thomas; Alexis A Thompson; Kevin McRedmond; J Michael Soucie; Harlan Austin; Bruce L Evatt
Journal:  N Engl J Med       Date:  2007-08-09       Impact factor: 91.245

View more
  2 in total

1.  Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress.

Authors:  Robert Ariens; Cecilia Becattini; Markus Bender; Wolfgang Bergmeier; Elisabetta Castoldi; Katrien Devreese; Martin Ellis; David Gailani; Vera Ignjatovic; Paula D James; Steven Kerrigan; Michele Lambert; Lai Heng Lee; Marcel Levi; Norma Maugeri; Joost Meijers; Juan Melero-Martin; Alan D Michelson; Federico Mingozzi; Keith Neeves; Heyu Ni; Anna-Karin Olsson; Zoltán Prohászka; Marie Ranson; Nicoletta Riva; Yotis Senis; Cornelia H van Ommen; Douglas E Vaughan; John Weisel
Journal:  Res Pract Thromb Haemost       Date:  2020-07-12

Review 2.  Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics.

Authors:  Nikoletta Pechlivani; Katherine J Kearney; Ramzi A Ajjan
Journal:  Int J Mol Sci       Date:  2021-11-21       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.